VIVOBIOT · NSE
Vivo Bio Tech Limited
₹16.08
-3.54% (-₹0.59)
Prev. close
₹16.67
Volume
16,987
Delivery %
85.5%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Vivo Bio Tech Limited
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, analytical, and other services. It also supplies specific pathogen free lab animals; breeders and distributes rodent models; and designs and develops of syngeneic / xenograft models for evaluation of anti-cancer agents evaluation, as well as offers custom rodent models, stem cell products, and lab animal diets. In addition, the company provides regulatory and non-regulatory IND preclinical development services; and screening and evaluating molecules for various pharmacological properties. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alangudi Sankaranarayanan F.C.P., Ph.D.
Headquarters
Hyderabad
Employees
247
Website
vivobio.comExchange
View on NSE ↗Key stats
Market cap
₹36.99 Cr
EPS (TTM)
₹-1.48
Beta (5Y monthly)
0.38
Shares float
80.92 L
EPS · quarter ended Jun 2026
₹0.08
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹51.78 Cr | ₹51.39 Cr | ₹52.23 Cr | ₹45.45 Cr | ₹46.67 Cr | ₹53.33 Cr | |
| EBITDA | ₹17.74 Cr | ₹15.91 Cr | ₹21.54 Cr | ₹21.13 Cr | ₹25.31 Cr | ₹21.29 Cr |
| ₹5.68 Cr | ₹2.20 Cr | ₹2.65 Cr | ₹2.53 Cr | ₹7.28 Cr | ₹-1.71 Cr | |
| Diluted EPS | ₹4.19 | ₹1.56 | ₹1.78 | ₹1.51 | ₹4.76 | ₹-0.82 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹79.52 Cr | ₹122.49 Cr | ₹123.03 Cr | ₹137.13 Cr | ₹143.23 Cr | ₹178.43 Cr | |
| ₹30.96 Cr | ₹67.44 Cr | ₹62.40 Cr | ₹73.06 Cr | ₹54.03 Cr | ₹67.38 Cr | |
| Stockholders' equity | — | ₹47.13 Cr | ₹51.87 Cr | ₹54.40 Cr | ₹77.90 Cr | ₹93.16 Cr |
Current assets, Non-current assets, CWIP, Others, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹14.83 Cr | ₹15.52 Cr | ₹11.83 Cr | ₹34.93 Cr | |
| Investing cash flow | — | — | ₹-4.00 Cr | ₹-7.95 Cr | ₹-15.84 Cr | ₹-59.35 Cr |
| — | — | ₹-11.18 Cr | ₹-7.56 Cr | ₹3.90 Cr | ₹24.57 Cr | |
| Capital expenditure | — | — | ₹-4.00 Cr | ₹-7.95 Cr | ₹-22.27 Cr | ₹-37.44 Cr |
| End cash position | — | — | ₹1.37 Cr | ₹1.39 Cr | ₹1.28 Cr | ₹1.44 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Vivo Bio Tech Limited | ₹36.99 Cr | ₹16.08 | — | 0.40 | -1.8% | 0.72 | +14.3% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.